Multiple myeloma with high-risk cytogenetics and its treatment approach
I Hanamura - International Journal of Hematology, 2022 - Springer
Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …
Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the …
M D'agostino, DA Cairns, JJ Lahuerta… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
How I treat high-risk multiple myeloma
Survival of multiple myeloma (MM) has significantly improved over the past decade;
however, a composed group of patients (15% to 20%), named high-risk (HR) MM, still …
however, a composed group of patients (15% to 20%), named high-risk (HR) MM, still …
Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk …
MF Kaiser, A Hall, K Walker, A Sherborne… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab,
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
A Chari, JL Kaufman, J Laubach, DW Sborov… - Blood cancer …, 2024 - nature.com
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus
lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed …
lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed …
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM),
yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational …
yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational …
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives
BA Costa, TH Mouhieddine, RJ Ortiz… - Critical Reviews in …, 2023 - Elsevier
From the 1960s to the early 2000s, alkylating agents (eg, melphalan, cyclophosphamide,
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …
and bendamustine) remained a key component of standard therapy for newly-diagnosed or …
Experts' consensus on the definition and management of high risk multiple myeloma
C Marcon, V Simeon, P Deias, G Facchin… - Frontiers in …, 2023 - frontiersin.org
High risk multiple myeloma (HRMM) at diagnosis is currently recognized according to the
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA …
F Efficace, G Gaidano, MT Petrucci… - The Lancet Healthy …, 2022 - thelancet.com
Background The clinical management of patients with relapsed or refractory multiple
myeloma is challenging and there is a paucity of tools to help clinicians make more informed …
myeloma is challenging and there is a paucity of tools to help clinicians make more informed …
Perspectives on the Treatment of Multiple Myeloma
The treatment of multiple myeloma has evolved significantly over the past few decades with
the development of novel therapeutics. The introduction of proteasome inhibitors …
the development of novel therapeutics. The introduction of proteasome inhibitors …